Ark Genomic Revolution Etf Shares Owned By Institutions
| ARKG Etf | USD 23.83 0.61 2.63% |
ARK Genomic Revolution fundamentals help investors to digest information that contributes to ARK Genomic's financial success or failures. It also enables traders to predict the movement of ARK Etf. The fundamental analysis module provides a way to measure ARK Genomic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARK Genomic etf.
ARK |
ARK Genomic Revolution ETF Shares Owned By Institutions Analysis
ARK Genomic's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of ARK Genomic Revolution are shares owned by institutions. This indicator is about the same for the ARK ETF Trust average (which is currently at 0.0) family and about the same as Health (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
Fund Asset Allocation for ARK Genomic
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides ARK Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
ARK Fundamentals
| Price To Earning | 41.86 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 7.63 X | |||
| Number Of Employees | 330 | |||
| Beta | 1.8 | |||
| Total Asset | 2.36 B | |||
| One Year Return | (13.60) % | |||
| Three Year Return | (28.30) % | |||
| Five Year Return | (5.30) % | |||
| Ten Year Return | 2.50 % | |||
| Net Asset | 2.36 B | |||
| Last Dividend Paid | 1.05 | |||
| Equity Positions Weight | 99.63 % |
About ARK Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARK Genomic Revolution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARK Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARK Genomic Revolution based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:Check out ARK Genomic Piotroski F Score and ARK Genomic Altman Z Score analysis. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.